Foresite Capital Management V LLC Sells 819,454 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Foresite Capital Management V LLC reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 46.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 939,860 shares of the company’s stock after selling 819,454 shares during the period. Hims & Hers Health accounts for about 18.9% of Foresite Capital Management V LLC’s holdings, making the stock its 2nd biggest holding. Foresite Capital Management V LLC owned 0.43% of Hims & Hers Health worth $22,726,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC increased its stake in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company’s stock worth $104,724,000 after acquiring an additional 40,447 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 1.2 %

Shares of HIMS opened at $52.04 on Friday. Hims & Hers Health, Inc. has a 12-month low of $12.07 and a 12-month high of $72.98. The stock has a market cap of $11.56 billion, a P/E ratio of 118.28 and a beta of 1.84. The company has a 50-day moving average of $32.97 and a two-hundred day moving average of $32.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s quarterly revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 3,236 shares of the firm’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $30.19, for a total transaction of $97,694.84. Following the sale, the insider now owns 159,662 shares in the company, valued at $4,820,195.78. This trade represents a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 650,500 shares of company stock valued at $25,790,311 over the last quarter. Insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent analyst reports. UBS Group restated a “mixed” rating on shares of Hims & Hers Health in a research report on Tuesday. Piper Sandler restated a “neutral” rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday. Bank of America increased their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research report on Tuesday, April 29th. Truist Financial decreased their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Finally, Leerink Partners increased their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $37.67.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.